MK-1088
MK-1088 is an orally active A2A/A2B adenosine receptor antagonist with human A2A Ki of 0.31 nM, human A2B Ki 5.3 nM. MK-1088 blocks receptor downstream signaling, inhibits CREB phosphorylation and reverses adenosine-mediated immunosuppression. MK-1088 restores TNF−α release and enhances tumor immune surveillance. MK-1088 can be used for the research of cancer[1].
For research use only. We do not sell to patients.
- CAS No.: 2433765-51-4
- Formula: C23H29FN8O2
- Molecular Weight:468.53
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Adenosine Receptor Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
hA2AAR 0.31 nM (Ki) |
hA2B 5.3 nM (Ki) |
hA1AR 82 nM (Ki) |
hA3 233 nM (Ki) |
In Vitro
MK-1088 (Compound 46) (60 min at room temperature) potently binds to hA2AR expressed in CHO cell membranes with a Ki of 0.31 nM[1].
MK-1088 (60 min at room temperature) binds to hA2BR with a Ki of 5.3 nM, showing a 16-fold lower potency relative to hA2BR[1].
MK-1088 (60 min at room temperature) binds to hA1R expressed in CHO-K1 cell membranes with a Ki of 82 nM, showing 259-fold lower potency relative to hA2AR[1].
MK-1088 (0.1 nM-100 μM) dose-dependently inhibits NECA-stimulated CREB phosphorylation in human CD4+ T cells with an IC50 of 70 nM[1].
MK-1088 dose-dependently recovers LPS (HY-D1056)-stimulated, NECA (HY-103173)-suppressed TNF-α release in human whole blood[1].
MK-1088 has a clean off-target profile for cardiac ion channels and most CYP enzymes, with only moderate inhibition of CYP3A4-midazolam (IC50 = 4.1 μM) and no time-dependent CYP3A4 inhibition[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
| Species | Dose | Route | CLunbound | Vd | T1/2 | Bioavailability |
|---|---|---|---|---|---|---|
| Rat[1] | 0.5 mg/kg | i.v. | 45.4 mL/min/kg | 9.3 L/kg | 2.3 h | / |
| Rat[1] | 3 mg/kg | p.o. | / | / | / | 36.8 % |
| Dog[1] | 0.1 mg/kg | i.v. | 6.6 mL/min/kg | 5.7 L/kg | 9.2 h | / |
| Dog[1] | 3 mg/kg | p.o. | / | / | / | 42.4 % |
| Rhesus monkey[1] | 0.5 mg/kg | i.v. | 45.2 mL/min/kg | 8.9 L/kg | 2.2 h | / |
| Rhesus monkey[1] | 3 mg/kg | p.o. | / | / | / | 51.4 % |
In Vivo
MK-1088 (30 mg/kg; p.o.; twice daily; 21 days) delivers 47% tumor growth inhibition as a single agent in mice bearing CM3 syngeneic tumors[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice (syngeneic tumor model)[1]
-
Dosage:30 mg/kg
-
Administration:p.o.; twice daily; 16 days
-
Result:Achieved 54% tumor growth inhibition (TGI) relative to control tumors at day 16, p < 0.0001 by one-way ANOVA.
Reached 97% A2AR target engagement based on mouse A2AR affinity (Ki = 6 nM) and 10 h unbound plasma exposure.
-
Animal Model:Mice (10 animals per group; syngeneic tumor model)[1]
-
Dosage:30 mg/kg
-
Administration:p.o.; twice daily; 21 days
-
Result:Afforded 47% tumor growth inhibition (TGI) as a single agent on study day 14.
Chemical Information
-
CAS No. 2433765-51-4
-
Molecular Weight 468.53
-
Formula C23H29FN8O2
-
SMILES
NC1=NC2=C(C=C(C(OC)=C2)F)C3=NC([C@@H]4CC[C@@H](N(C4)C5=CN(N=C5)CC(O)(C)C)C)=NN31
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)